MwanzoBMY • BCBA
add
Bristol-Myers Squibb Co Cedear
Bei iliyotangulia
$Â 9,970.60
Thamani ya kampuni katika soko
127.01B USD
Uwiano wa bei na mapato
-
Mgao wa faida
-
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 12.50B | 1.30% |
Matumizi ya uendeshaji wa biashara | 5.47B | -13.56% |
Mapato halisi | 1.09B | 1,409.72% |
Kiwango cha faida halisi | 8.69 | 1,398.28% |
Mapato kwa kila hisa | 1.26 | -24.55% |
EBITDA | 4.54B | -2.17% |
Asilimia ya kodi ya mapato | 26.12% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 10.67B | -1.71% |
Jumla ya mali | 90.04B | -2.77% |
Jumla ya dhima | 71.53B | -6.14% |
Jumla ya hisa | 18.51B | — |
hisa zilizosalia | 2.04B | — |
Uwiano wa bei na thamani | elfu 1.10 | — |
Faida inayotokana na mali | 9.42% | — |
Faida inayotokana mtaji | 13.01% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.09B | 1,409.72% |
Pesa kutokana na shughuli | 1.97B | -55.53% |
Pesa kutokana na uwekezaji | -1.46B | -643.88% |
Pesa kutokana na ufadhili | -6.03B | -267.17% |
Mabadiliko halisi ya pesa taslimu | -5.51B | -324.45% |
Mtiririko huru wa pesa | 669.62M | -84.21% |
Kuhusu
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1887
Makao Makuu
Tovuti
Wafanyakazi
32,500
